Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.
Despite widespread commercial acceptance of botulinum toxin (BTX) for idiopathic cervical dystonia (ICD), no follow up has been performed to determine when and why some patients stop therapy. It has been suggested that some patients who stop BTX treatment may do so because of permanent improvement. We surveyed 155 patients with ICD who were treated over 6 years with BTX to determine when and why patients stopped treatment with BTX, and what adverse events and changes in dose and/or frequency of treatments occurred in those who continued treatment. Of the 133 (86.6%) individuals returning the surveys, 104 continued on BTX treatment and 29 had stopped therapy. Of the 29 subjects no longer receiving BTX, 11 individuals had only received one or two injections. Prior surgical treatment for ICD did not influence their decision to stop therapy. Of those 104 of 133 continuing on BTX treatments, two thirds of the subjects reported the injections always help, whereas one quarter estimated one set of injections did not help. One third of those continuing treatment reported the first injection was most helpful, whereas another one third felt all injections were similarly effective. After an initial adjustment, BTX dosages and frequency of treatment remained stable in this group.
Brashear
A
A
Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.
Bergan
K
K
Wojcieszek
J
J
Siemers
E R
ER
Ambrosius
W
W
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D017060:Patient Satisfaction; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A